Responses
Perspective
Ranibizumab (Lucentis) versus bevacizumab (Avastin): modelling cost effectiveness
Compose a Response to This Article
Other responses
Jump to comment:
- Published on: 30 November 2007
- Published on: 30 November 2007We are part of the problemShow More
Dear Editor
We read with great interest the report by Raftery et al on Ranibizumab (Lucentis) versus bevacizumab (Avastin): modelling cost effectiveness. The authors raise the very pertinent point in respect to a single company owning two competing drugs and the inherent cost to tax payers. The authors conclude their abstract with "Public pressure may be the most potent weapon in persuading Genentech to license bevaciz...
Conflict of Interest:
None declared.